PMID- 22425139
OWN - NLM
STAT- MEDLINE
DCOM- 20120827
LR  - 20120430
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 58
IP  - 3
DP  - 2012 Jun
TI  - Monocyte chemoattractant protein-1 in schizophrenia: -2518A/G genetic variant and 
      protein levels in Armenian population.
PG  - 351-4
LID - 10.1016/j.cyto.2012.02.013 [doi]
AB  - Monocyte chemoattractant protein-1 (MCP-1) has been proposed as a contributory 
      factor in pathophysiology of schizophrenia. The aim of the current study was to 
      explore the possible association of the MCP-1-2518A/G genetic polymorphism and 
      plasma levels of MCP-1 in patients with paranoid schizophrenia. The MCP-1-2518A/G 
      (rs1024611) polymorphism and blood levels of MCP-1 in patients with paranoid 
      schizophrenia and healthy subjects were evaluated and compared. One hundred and 
      three chronic patients with paranoid schizophrenia treated with neuroleptics and 
      105 healthy subjects were genotyped using polymerase chain reaction with 
      sequence-specific primers (PCR-SSP) and their MCP-1 plasma levels were measured 
      by a solid-phase enzyme-linked immunosorbent assay (ELISA). When comparisons were 
      made between patients and controls, the frequency of the MCP-1-2518*G minor 
      allele (35% vs 23%, p=0.009, OR=1.77, 95% CI: 1.1-2.04) and also of the 
      MCP-1-2518*G carriers (60% vs 40%, p=0.003, OR=2.27, 95% CI: 1.13-2.01) were 
      higher in patients. The mean value of the MCP-1 plasma level in patients with 
      schizophrenia was significantly higher than in controls. Interestingly, the 
      patients with the GG genotype had the highest MCP-1 level (711.4 +/- 211.4 pg/ml), 
      followed by those with the AG genotype (472.1 +/- 135.8 pg/ml) and AA (372.4 +/- 
      180.2 pg/ml) homozygotes. In conclusion, we report here the association of the 
      -2518A/G genetic polymorphism and increased plasma levels of MCP-1 with 
      schizophrenia and nominate -2518*G minor allele as a risk factor for 
      schizophrenia in Armenian population.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Zakharyan, Roksana
AU  - Zakharyan R
AD  - Laboratory of Macromolecular Complexes, Institute of Molecular Biology, National 
      Academy of Sciences of the Republic of Armenia, 7 Hasratyan St., 0014 Yerevan, 
      Armenia. r_zakharyan@mb.sci.am
FAU - Boyajyan, Anna
AU  - Boyajyan A
FAU - Arakelyan, Arsen
AU  - Arakelyan A
FAU - Melkumova, Maya
AU  - Melkumova M
FAU - Mrazek, Frantisek
AU  - Mrazek F
FAU - Petrek, Martin
AU  - Petrek M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120317
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/therapeutic use
MH  - Armenia
MH  - Case-Control Studies
MH  - Chemokine CCL2/genetics/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Genetic
MH  - Schizophrenia/drug therapy/genetics/*metabolism
EDAT- 2012/03/20 06:00
MHDA- 2012/08/28 06:00
CRDT- 2012/03/20 06:00
PHST- 2011/06/22 00:00 [received]
PHST- 2012/02/22 00:00 [accepted]
PHST- 2012/03/20 06:00 [entrez]
PHST- 2012/03/20 06:00 [pubmed]
PHST- 2012/08/28 06:00 [medline]
AID - S1043-4666(12)00065-8 [pii]
AID - 10.1016/j.cyto.2012.02.013 [doi]
PST - ppublish
SO  - Cytokine. 2012 Jun;58(3):351-4. doi: 10.1016/j.cyto.2012.02.013. Epub 2012 Mar 
      17.